Northwire Canada EditionWednesday, July 22, 2026
Northwire
UTWO 0.400 −11.1% IVN 10.61 −1.5% MUX 25.41 +1.6% LOD 0.310 +5.1% CLZ 0.045 +12.5% CNL 18.65 +2.2% LAM 0.510 +2.0% STS 0.165 +10.0% GR 0.070 +7.7% RARE 9.25 +3.9% PWM 0.640 −1.5% KNG 1.11 +8.8% TMET 0.115 +15.0% TNR 0.250 +0.0% AGX 0.700 +1.4% CANX 0.235 −4.1% UTWO 0.400 −11.1% IVN 10.61 −1.5% MUX 25.41 +1.6% LOD 0.310 +5.1% CLZ 0.045 +12.5% CNL 18.65 +2.2% LAM 0.510 +2.0% STS 0.165 +10.0% GR 0.070 +7.7% RARE 9.25 +3.9% PWM 0.640 −1.5% KNG 1.11 +8.8% TMET 0.115 +15.0% TNR 0.250 +0.0% AGX 0.700 +1.4% CANX 0.235 −4.1%
Production / Operations Material +

Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt

From the Earth to the Bottle: Vertical Integration of the Contrast Media Supply Chain

Executive Summary

The most recent news (March 4, 2026) confirms that Voyageur’s natural barite from its Frances Creek project has achieved 98.8% purity, exceeding the United States Pharmacopeia (USP) requirement of 97.5%. This validates the "Mueller Process" and the company's ability to produce Active Pharmaceutical Ingredients (API) from its own mineral resource. Furthermore, the company has secured a grant from Alberta Innovates to progress to Health Canada human trials, with clinical trials expected to complete in Q4 2026. This follows a major February 2023 announcement of a collaboration with Bayer for iodine extraction, involving up to USD$2.35 million in milestone-based funding.

Material Impact

The news is Material - Positive because it provides technical validation of the company's core thesis: that natural barite can replace expensive synthetic alternatives. - De-risking: Achieving 98.8% purity is a critical hurdle for pharmaceutical regulatory approval. It proves the resource is "pharmaceutical grade." - Non-dilutive Funding: The Alberta Innovates grant and the Bayer milestone payments (USD$350k initial) provide essential capital without further diluting shareholders at low price levels. - Strategic Validation: The exclusivity agreement with Bayer for iodine offtake validates Voyageur’s potential as a serious player in the global contrast media supply chain, moving beyond a junior mining narrative into a biotech/med-tech hybrid. - Commercial Progress: The transition from "bench-scale" to "human trials" and "commercial shipments" (initiated June 2025) shows a clear progression toward revenue generation.

VM · Price
Company Overview

Voyageur is developing a vertically integrated "Earth to Bottle" model for radiology contrast media (Barium and Iodine). - Flagship Project: Frances Creek (British Columbia), a high-grade barite deposit. - Strategy: Replace synthetic barium (costing ~$10,000/tonne) with natural barite (estimated production cost ~$650/tonne), targeting a 70%+ gross margin. - Secondary Project: Iodine extraction from oilfield brines in Oklahoma/Utah using the proprietary Mueller Process.

Read the original news release →

More from Voyageur Pharmaceuticals Ltd.